Patents by Inventor James Monn

James Monn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS
    Publication number: 20260055116
    Abstract: The invention provides substituted tetrahydropyrrolo-pyridinone compounds, pharmaceutical compositions, and their use in treating muscarinic acetylcholine receptor mediated disorders.
    Type: Application
    Filed: July 25, 2025
    Publication date: February 26, 2026
    Inventors: Kevin Matthew Gardinier, James Edmund Audia, James Monn, Jason Myers, Nadia M. Ahmad, Emanuela Gancia, Niall Wagstaff, David G. Evans, Fabien Jean Ghislain Roussel, Elizabeth Anne Skidmore
  • Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions
    Patent number: 12421242
    Abstract: The invention provides substituted tetrahydropyrrolo-pyridinone compounds, pharmaceutical compositions, and their use in treating muscarinic acetylcholine receptor mediated disorders.
    Type: Grant
    Filed: June 11, 2024
    Date of Patent: September 23, 2025
    Assignee: Karuna Therapeutics, Inc.
    Inventors: Kevin Matthew Gardinier, James Edmund Audia, James Monn, Jason Myers, Nadia M. Ahmad, Emanuela Gancia, Niall Wagstaff, David G. Evans, Fabien Jean Ghislain Roussel, Elizabeth Anne Skidmore
  • SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS
    Publication number: 20240336619
    Abstract: The invention provides substituted tetrahydropyrrolo-pyridinone compounds, pharmaceutical compositions, and their use in treating muscarinic acetylcholine receptor mediated disorders.
    Type: Application
    Filed: June 11, 2024
    Publication date: October 10, 2024
    Inventors: Kevin Matthew Gardinier, James Edmund Audia, James Monn, Jason Myers, Nadia M. Ahmad, Emanuela Gancia, Niall Wagstaff, David G. Evans, Fabien Jean Ghislain Roussel, Elizabeth Anne Skidmore
  • PRODRUGS OF EXCITATORY AMINO ACIDS
    Publication number: 20070265342
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Application
    Filed: July 5, 2007
    Publication date: November 15, 2007
    Inventors: David Coffey, James Monn, Concepcion Pedregal-Tercero, Steven Pedersen
  • Prodrugs of excitatory amino acids
    Publication number: 20050222231
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Application
    Filed: June 6, 2003
    Publication date: October 6, 2005
    Applicant: ELI LILLY AND COMPANY
    Inventors: Eric Moher, James Monn, Concepcion Pedregal-Tercero
  • Prodrugs of excitatory amino acids
    Publication number: 20050009912
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs of formula (I) wherein the residue R11, R12 and R13 are aas defined in claim 1. The invention further relates to processes for the preparation of the compounds of formula (I), and to pharmaceutical compositions for the treatment of neurological and psychiatric disorders comprising said compounds.
    Type: Application
    Filed: December 5, 2002
    Publication date: January 13, 2005
    Inventors: Ana Bueno Melendo, Alfonso De Dios, Carmen Dominguez-Fernandez, Rafael Ferritto Crespo, Jose Martin, Maria Martinez-Grau, Steven Massey, James Monn, Concepcion Pedregal-Tercero, Matthew Valli, Marc Herin
  • Partial agonists of the strychnine insensitive glycine modulatory site of the N-methyl-D-aspartate receptor complex as neuropsychopharmacological agents
    Patent number: 6017957
    Abstract: A method is disclosed for the treatment of neuropsychopharmacological disorders which are associated with or result from excessive activation of the N-methyl-D-aspartate receptor complex, which method comprises administering an effective neuropsychopharmacological disorder-treating amount of a compound possessing partial agonist properties for the strychnine insensitive glycine modulatory sites of N-methyl-D-aspartate receptors. Exemplary of partial agonists which are useful in the method of the invention are 1-aminocyclopropanecarboxylic acid, and associated derivates thereof. Novel injectable pharmaceutical compositions are also disclosed.
    Type: Grant
    Filed: August 8, 1989
    Date of Patent: January 25, 2000
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Phil Skolnick, Anita Lewin, Juan-Carlos Marvizon, James Monn, Kenner Rice